Monte Rosa Therapeutics (GLUE) EBT Growth (1y) (2021 - 2026)
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) EBT Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 8.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.60% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 88.92% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 6.23% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 213.87% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 530.43% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -12.04% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 96.45% |
| 10 | Monte Rosa Therapeutics | 1.41 Bn | 781.72 Mn | - | -289.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -289.23% |
| Mar 31, 2026 | -193.18% |
| Dec 31, 2025 | -395.34% |
| Sep 30, 2025 | -27.20% |
| Jun 30, 2025 | 63.08% |
| Mar 31, 2025 | 249.62% |
| Dec 31, 2024 | 146.89% |
| Sep 30, 2024 | 31.47% |
| Jun 30, 2024 | 14.09% |
| Mar 31, 2024 | 0.48% |
| Dec 31, 2023 | -8.10% |
| Sep 30, 2023 | -27.07% |
| Jun 30, 2023 | -32.18% |
| Mar 31, 2023 | -32.65% |
| Dec 31, 2022 | -31.69% |
| Sep 30, 2022 | -37.59% |
| Jun 30, 2022 | -46.16% |
| Mar 31, 2022 | -110.06% |
| Dec 31, 2021 | -95.98% |
| Sep 30, 2021 | -211.01% |